Subscribe to RSS
Download PDF
DOI: 10.1055/a-2306-0804
Clinical Pathways and Outcomes of Andexanet Alfa Administration for the Reversal of Critical Bleeding in Patients on Oral Direct Factor Xa Inhibitors
Funding This work was supported by AstraZeneca Pharmaceuticals, PC, and by funding from the Broxmeyer Fellowship in Clinical Thrombosis. The funders had no role in study design or conduct; data collection or analysis; preparation, review, or writing of the manuscript; or decision to submit the manuscript for publication.
Abstract
Background Andexanet is U.S. Food and Drug Administration (FDA) approved for the reversal of critical bleeding from factor Xa inhibitors and off-label for surgical reversal. Data are lacking on andexanet administration processes.
Methods We retrospectively studied patients at a 23-hospital system who received andexanet from November 2019 to March 2023. Abstractors coded demographics, comorbidities, anticoagulant use, andexanet indication, and process times. The primary outcome was presentation-to-andexanet time; diagnosis, ordering, and administration times were calculated. Secondary outcomes included in-hospital postandexanet major thromboembolism/bleeding and mortality.
Results In total, 141 patients were analyzed. Andexanet indications were predominantly neurologic bleeding (85.8%). Twenty-four patients (17.0%) were transferred from nontertiary/academic centers to tertiary/academic centers. The median presentation-to-administration time was 192.5 minutes (interquartile range [IQR]: 108.0–337.0 minutes). Components were as follows: 72.5 minutes (IQR: 39.0–137.5 minutes) for bleeding diagnosis; 35.5 minutes (IQR: 0–96.5 minutes) for andexanet ordering; and 53.0 minutes (IQR: 38.5–78.5 minutes) for administration, which was longer at tertiary/academic hospitals (ratio 1.5, 95% confidence interval [CI]: 1.2–2.0, p = 0.002). Gastrointestinal or other critical bleeding (ratio 2.59, 95% CI: 1.67–4.02, p < 0.001), and tertiary/academic center treatment (ratio 1.58, 95% CI: 1.15–2.18, p = 0.005), were associated with increased time. Major thromboembolism, bleeding, and mortality occurred in 10.6, 12.0, and 22.9% of patients, respectively.
Conclusions In our cohort, the median presentation-to-administration time was over 3 hours. Cumulative times were longer at tertiary/academic hospitals and for gastrointestinal/other bleeding. Postandexanet major thromboembolism/bleeding occurred more at tertiary/academic hospitals, possibly related to transfers. Prospective studies may elucidate clinical decision-making bottlenecks.
Disclosures
Dr. Spyropoulos reports honoraria from Janssen, Bayer, Bristol Myers Squibb, Pfizer, AstraZeneca, and Sanofi and research grants from Janssen and Boehringer Ingelheim. He also is a member of the ATLAS group, an academic research organization. Dr. Goldin reports grant support from Janssen outside of the submitted work. The other authors report no conflicts.
Publication History
Received: 16 January 2024
Accepted: 08 April 2024
Accepted Manuscript online:
15 April 2024
Article published online:
13 May 2024
© 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
References
- 1 Heo Y-A. Andexanet alfa: first global approval. Drugs 2018; 78 (10) 1049-1055
- 2 Milling Jr TJ, Middeldorp S, Xu L. et al. ANNEXA-4 Investigators. Final Study report of andexanet alfa for major bleeding with factor Xa inhibitors. Circulation 2023; 147 (13) 1026-1038
- 3 Sarode R, Milling Jr TJ, Refaai MA. et al. Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study. Circulation 2013; 128 (11) 1234-1243
- 4 Majeed A, Ågren A, Holmström M. et al. Management of rivaroxaban- or apixaban-associated major bleeding with prothrombin complex concentrates: a cohort study. Blood 2017; 130 (15) 1706-1712
- 5 Schulman S, Gross PL, Ritchie B. et al. Study Investigators. Prothrombin complex concentrate for major bleeding on factor Xa inhibitors: a prospective cohort study. Thromb Haemost 2018; 118 (05) 842-851
- 6 Tomaselli GF, Mahaffey KW, Cuker A. et al. 2020 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol 2020; 76 (05) 594-622
- 7 Cuker A, Burnett A, Triller D. et al. Reversal of direct oral anticoagulants: guidance from the anticoagulation forum. Am J Hematol 2019; 94 (06) 697-709
- 8 Baugh CW, Levine M, Cornutt D. et al. Anticoagulant reversal strategies in the emergency department setting: recommendations of a multidisciplinary expert panel. Ann Emerg Med 2020; 76 (04) 470-485
- 9 Sheth KN, Solomon N, Alhanti B. et al. Time to anticoagulation reversal and outcomes after intracerebral hemorrhage. JAMA Neurol [Internet] 2024 [cited 2024 Feb 28]. Accessed April 23, 2024 at: https://jamanetwork-com.accesdistant.sorbonne-universite.fr/journals/jamaneurology/fullarticle/2815044
- 10 Li Q, Yakhkind A, Alexandrov AW. et al. Code ICH: a call to action. Stroke 2024; 55 (02) 494-505
- 11 Kubica J, Adamski P, Gajda R. et al. Andexanet alfa—recommendations for clinical use. Multidisciplinary experts' standpoint. Cardiol J 2023; 30 (04) 502-505
- 12 Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009; 42 (02) 377-381
- 13 Harris PA, Taylor R, Minor BL. et al; REDCap Consortium. The REDCap consortium: building an international community of software platform partners. J Biomed Inform 2019; 95: 103208
- 14 Schulman S, Kearon C. Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005; 3 (04) 692-694
- 15 Demchuk AM, Yue P, Zotova E. et al. ANNEXA-4 Investigators. Hemostatic efficacy and anti-FXa (Factor Xa) reversal with andexanet alfa in intracranial hemorrhage: ANNEXA-4 substudy. Stroke 2021; 52 (06) 2096-2105
- 16 Bradshaw PG, Keegan SP, Droege ME. et al. Reversal of apixaban and rivaroxaban with andexanet alfa prior to invasive or surgical procedures. Pharmacotherapy 2022; 42 (10) 780-791
- 17 Barra ME, Das AS, Hayes BD. et al. Evaluation of andexanet alfa and four-factor prothrombin complex concentrate (4F-PCC) for reversal of rivaroxaban- and apixaban-associated intracranial hemorrhages. J Thromb Haemost 2020; 18 (07) 1637-1647
- 18 Connolly SJ, Milling Jr TJ, Eikelboom JW. et al. ANNEXA-4 Investigators. Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. N Engl J Med 2016; 375 (12) 1131-1141
- 19 Glancy P, Sutton DJ, Gomez K, Nicolson PLR, Buka RJ. How will UK hospitals use andexanet alfa? A review of local protocols. eJHaem 2023; 4 (01) 298-300